- Ph.D., Rutgers University, 1995
- Postdoctoral Fellow, Case Western Reserve University School of Medicine, 1995-1997
The overall theme of research in our laboratory is to study signal transduction within eukaryotic cells. We are particularly interested in elucidating the functions of protein kinases and nuclear receptors which are deregulated in human prostate cancer, namely Src, Etk/BMX, Pim-1 and androgen receptor. We and others demonstrated that deregulation of these signaling molecules may play an important role in development of therapeutic resistance in human prostate cancers. Studying the mechanisms by which these proteins regulate their downstream signaling effectors in cancer models will allow us to design new effective drugs against cancer in the future.
Lab Techniques and Equipment:
Cell culture and transfection; Molecular cloning and site mutagenesis; real-time PCR, Immunoprecipitation and Western blot; ChIP assays, Immunocytochemistry; Transgenic mice; In vivo tumor models; Yeast two-hybrid system; Microarrays
- Ph.D., Rutgers University, 1995
- Postdoc, Case Western Reserve University School of Medicine, 1995-1997
- Riyan Chen, Ph.D.,(1999-2001), Research Associate, McGill University, Canada
- Jianbo Yang, MD., Ph.D., (2000-2002), Research Associate, University of Minnesota
- Oekyung Kim, Ph.D.,(2000-2002), Assistant Professor, Pohang University of Science & Technology, Korea
- Tianyun Jiang, MD, (2002-2005), Research Associate, JHU
- Ying-qiu Xie, Ph.D., (2002-2007), Research Associate, University of Miami
- Bojie Dai, Ph.D., (2003-2007), Research Associate, University of Maryland
- Zhiyong Guo, MD., Ph.D., 2003 - present, Research Associate, DOD postdoctoral fellowship awardee
- Feng Sun, Ph.D., 2007 - present
- Xi Yang, Ph.D., 2007 - present
- Hege Chen, Ph.D., 2008 - present
- Wei Li, MD, Ph.D., 2008 - present
- Miyoung Kang (2002-2004), MS
- Issa Neshiewat (2003-2005), MS
- Kexin Xu (2003 - 2008), Ph.D., DOD predoctoral fellowship awardee. Currently a postdoc fellow at Harvard Medical School.
- Douglas Linn (2006 - present), BS, DOD predoctoral fellowship awardee
- Hermela Shimelis (2007 - present), MS, DOD predoctoral fellowship awardee
- Alan Alfano (2010 - present), BS
Qiu, Y., Ravi, L. and Kung, H-J. 1998. Requirement of erbB2 for activation of MAP kinase by Interleukin-6 in Prostate Cancer cells. Nature, 393: 83-85.
Qiu, Y., Robinson, D., Pretlow, T. and Kung, H-J. 1998. Etk, a tyrosine kinase with a PH domain, is an effector of PI3 Kinase and involved in IL6 induced neuroendocrine differentiation of prostate cancer cells. Proc. Natl. Acad. Sci., 95: 3644-3649.
Chen, R., Kim, O., Li, M., Xiong, X., Guan, J-L., Kung, H-J., Chen, H., Shimizu, Y. and Qiu, Y. 2001. Regulation of the PH-domain-containing tyrosine kinase Etk by Focal Adhesion Kinase through the FERM Domain. Nature Cell Biology, 3: 439-444.
Jiang, T., Guo, Z., Dai, B., Kang, M., Ann, D. K., Kung, H-J. and Qiu, Y. 2004. Bi-directional Regulation between Tyrosine Kinase Etk/BMX and Tumor Suppressor p53 in Response to DNA Damage. J. Biol. Chem., 279: 50181 - 50189.
Xie, Y., Xu, K., Dai, B., Guo, Z., Jiang, T., Chen, H. and Qiu, Y. 2006. The 44 kd Pim-1 Kinase Directly Interacts with Tyrosine Kinase Etk/BMX and Protects Human Prostate Cancer Cells from Apoptosis Induced by Chemotherapeutic Drugs. Oncogene 25, 70-78.
Dai, B., Kim, O., Xie, Y., Guo, Z., Xu, K., Kong, X., Melamed, J., Chen, H., Bieberich, C.J., Borowsky, A.D., Kung, HJ, Wei, G., Ostrowski, M.C., Brodie, A., and Qiu, Y. 2006. Tyrosine Kinase Etk/Bmx Is Upregulated in Human Prostate Cancer and Its Overexpression Induces Prostate Intraepithelial Neoplasia in Mouse. Cancer Research 66: 8058-8064.
Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., Nesheiwat, I., Kong, X., Melamed, J., Handratta, V.D., Njar, V.C.O., Brodie, A.M.H., Yu, LR, Veenstra,T.D., Chen, H., and Qiu, Y. 2006. Regulation of Androgen Receptor by Tyrosine Phosphorylation. Cancer Cell, 10:309-319.
Xie, Y, Xu, K, Linn, D., Guo, Z., Nakanishi, T., Ross, D., Chen, H., Fazli, L., Gleave, M. E. and Qiu, Y. 2008. The 44 kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and promotes its drug resistant activity in human prostate cancer cells. J. Biol. Chem., 283:3349-56.
Guo Z., Yang X., Sun F., Jiang R, Linn DE, Chen H, Chen H., Kong X, Melamed J, Tepper CG, Kung H-J, Brodie AMH, Edwards J, and Qiu, Y. A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth. Cancer Research, 69: 2305-13, 2009.
Xu, K., Shimelis, H., Linn, DE., Jiang, R., Yang, X., Sun, F., Guo, Z., Chen, H., Li, W., Chen, H., Kong, X., Melamed, J., Fang, S., Xiao, Z., Veenstra, TD., and Qiu, Y. Regulation of Androgen Receptor Transcriptional Activity and Specificity by RNF6-induced Ubiquitination. Cancer Cell, 15: 270-282, 2009.
Dai, B., Chen H-G., Guo, S., Yang X., Sun F., Linn DE, Li, W., Guo Z., Kong X, Melamed J, Qiu, S, Chen H., and Qiu, Y. 2010. Compensatory up-regulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells. Cancer Res, 70, 5587-5596.
Linn, DE, Yang, X., Sun, F., Xie, Y., Chen, H., Jiang, R., Chen, H., Chumsri, S., Burger, AM and Qiu, Y. 2010. A role for OCT4 in tumor initiation of drug-resistant prostate cancer. Genes & Cancer, in press.